<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 2.6: Assessing Cardiovascular Risk Factors in Clients</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - RED/GOLD theme for Cardiovascular Health */
        .module-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #dc2626;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #dc2626;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #fef2f2;
            border: 2px solid #ef4444;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #ef4444;
        }

        .term-item .term {
            font-weight: 700;
            color: #991b1b;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #991b1b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #fee2e2 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #fff1f2 0%, #ffe4e6 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #fecdd3;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #991b1b;
            font-weight: 600;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #ef4444, #991b1b);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        /* Data Table */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            background: white;
        }

        th {
            background: #f8f9fa;
            color: #991b1b;
            font-weight: 600;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #eee;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
        }

        /* Check Understanding */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #dc2626;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .reveal-btn:hover {
            background: #991b1b;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #b91c1c;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #fef2f2;
            border-radius: 8px;
            line-height: 1.6;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways */
        .takeaways-box {
            background: linear-gradient(135deg, #f5f5f5 0%, #e8e8e8 100%);
            padding: 22px 25px;
            margin-top: 35px;
            border-radius: 8px;
            border: 1px solid #ddd;
        }

        .takeaways-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 15px 0;
            font-size: 16px;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* References */
        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #f9f9f9;
            border-radius: 12px;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-top: 0;
        }

        .references-list {
            list-style: none;
            padding: 0;
        }

        .references-list li {
            margin-bottom: 8px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }

        .lesson-footer .brand {
            color: #991b1b;
            font-weight: 600;
            margin: 0;
            font-size: 15px;
        }

        .lesson-footer .copyright {
            color: #888;
            font-size: 13px;
            margin: 10px 0 0 0;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 2: Vascular & Bone Integrity (The 'V' in VITAL)</p>
            <h1 class="lesson-title">Lesson 2.6: Assessing Cardiovascular Risk Factors in Clients</h1>
            <div class="lesson-meta">
                <span class="meta-item">30 min read</span>
                <span class="meta-item">Lesson 6 of 8</span>
            </div>
        </header>

        <!-- Table of Contents -->
        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Estrogen Shield & Its Withdrawal</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Menopause-Specific Risk Factors</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Screening Tools & Risk Calculators</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Interpreting Key Biomarkers</a></li>
                <li><a href="#section5"><span class="section-num">5</span>The VITAL Assessment Protocol</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Case Studies & Clinical Application</a></li>
            </ul>
        </div>

        <!-- Learning Objectives -->
        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the physiological mechanisms by which estrogen decline increases cardiovascular disease (CVD) risk.</li>
                <li>Identify "Risk Enhancers" specific to the menopausal transition, including early menopause and vasomotor symptoms.</li>
                <li>Interpret lipid profiles and inflammatory markers using menopause-specific reference ranges.</li>
                <li>Utilize validated cardiovascular risk estimators (ASCVD, MESA) to categorize client risk levels.</li>
                <li>Establish a professional screening protocol for non-clinical practitioners to identify high-risk clients for medical referral.</li>
            </ul>
        </div>

        <!-- Welcome Box -->
        <div class="welcome-box">
            <h3>The Silent Transition: Heart Health in Menopause</h3>
            <p>While hot flashes and night sweats dominate the conversation, the most profound impact of the menopausal transition occurs within the <span class="highlight">vascular endothelium</span>. Cardiovascular disease remains the leading cause of death for women globally, yet risk is often underestimated during perimenopause. As a Menopause Support Coach, your ability to assess these "invisible" risk factors is critical to the 'V' (Vascular) pillar of the VITAL Method‚Ñ¢. You are the front line in identifying shifts in metabolic and vascular health before they manifest as clinical events.</p>
        </div>

        <!-- Key Terms -->
        <div class="key-terms-box">
            <p class="box-label">üî¨ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Endothelial Dysfunction</p>
                    <p class="definition">The loss of the blood vessel's ability to dilate appropriately, often the first step in the development of atherosclerosis, accelerated by estrogen loss.</p>
                </div>
                <div class="term-item">
                    <p class="term">ApoB (Apolipoprotein B)</p>
                    <p class="definition">A primary structural protein of all potentially atherogenic (plaque-forming) lipoproteins; a more accurate risk marker than LDL-C alone.</p>
                </div>
                <div class="term-item">
                    <p class="term">Vasomotor Symptoms (VMS)</p>
                    <p class="definition">Hot flashes and night sweats; frequent or severe VMS are now recognized as early clinical markers of increased cardiovascular risk.</p>
                </div>
                <div class="term-item">
                    <p class="term">hs-CRP</p>
                    <p class="definition">High-sensitivity C-reactive protein; a biomarker of systemic inflammation that predicts future cardiovascular events.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Estrogen Shield & Its Withdrawal</h2>

        <p>Before menopause, women generally enjoy a lower risk of cardiovascular disease compared to men of the same age. This "estrogen shield" is primarily mediated through <span class="highlight">Nitric Oxide (NO) production</span>. Estrogen receptors in the vascular wall stimulate the enzyme endothelial nitric oxide synthase (eNOS), which keeps blood vessels flexible, dilated, and resistant to plaque formation.</p>

        <p>A 2022 systematic review published in <i>The Lancet</i> highlighted that the transition to menopause is associated with a <span class="highlight">rapid acceleration</span> in subclinical atherosclerosis. As estrogen levels fluctuate and eventually decline, we observe three primary vascular shifts:</p>
        
        <ul class="content-list">
            <li><strong>Reduced Vasodilation:</strong> Arteries become "stiffer" (increased pulse wave velocity), leading to higher systolic blood pressure.</li>
            <li><strong>Pro-Inflammatory Shift:</strong> The loss of estrogen's anti-inflammatory effect allows for an increase in cytokines like IL-6 and TNF-alpha.</li>
            <li><strong>Adverse Lipid Remodeling:</strong> A shift from large, buoyant LDL particles to small, dense, highly atherogenic particles.</li>
        </ul>

        <!-- Statistics Box -->
        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">1 in 3</div>
                    <div class="stat-label">Women die of CVD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">15%</div>
                    <div class="stat-label">Rise in LDL-C post-meno</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">2.6x</div>
                    <div class="stat-label">Risk with early meno</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">50%+</div>
                    <div class="stat-label">Increase in HTN risk</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Menopause-Specific Risk Factors</h2>

        <p>Traditional risk calculators (like the Framingham Risk Score) often fail to account for the unique variables of the female reproductive life cycle. To provide "Premium" coaching, you must look beyond standard markers and evaluate <span class="highlight">Menopause-Specific Risk Enhancers</span>.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Risk Factor</th>
                        <th>Impact on Cardiovascular Risk</th>
                        <th>Coaching Consideration</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Early Menopause (<45y)</strong></td>
                        <td>Increased lifetime exposure to low estrogen states.</td>
                        <td>Higher urgency for lifestyle & medical intervention.</td>
                    </tr>
                    <tr>
                        <td><strong>Severe VMS</strong></td>
                        <td>Frequent hot flashes correlate with lower endothelial function.</td>
                        <td>VMS are a "window" into vascular health.</td>
                    </tr>
                    <tr>
                        <td><strong>PCOS History</strong></td>
                        <td>Lifetime of insulin resistance and androgen excess.</td>
                        <td>Higher risk of metabolic syndrome in menopause.</td>
                    </tr>
                    <tr>
                        <td><strong>Adverse Pregnancy</strong></td>
                        <td>History of Preeclampsia or Gestational Diabetes.</td>
                        <td>Permanent vascular changes that manifest in menopause.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">Screening Tools & Risk Calculators</h2>

        <p>While you are not diagnosing disease, using validated tools allows you to quantify risk and communicate effectively with a client's medical team. The <span class="highlight">ASCVD (Atherosclerotic Cardiovascular Disease) Risk Estimator Plus</span> is the current gold standard for 10-year risk prediction.</p>

        <p>However, for women in their 40s and early 50s, the 10-year risk may appear "low" simply because of age, even if their vascular health is deteriorating. In these cases, we look at <span class="highlight">Relative Risk</span> and "Risk Enhancers" as defined by the American Heart Association (AHA):</p>

        <ul class="content-list">
            <li><strong>MESA Risk Score:</strong> Incorporates Coronary Artery Calcium (CAC) scores, which is the most accurate predictor of actual plaque burden in menopausal women.</li>
            <li><strong>Blood Pressure Monitoring:</strong> A "normal" BP of 120/80 in a 30-year-old may be "elevated" if it was 100/60 prior to the menopausal transition.</li>
        </ul>

        <h2 id="section4">Interpreting Key Biomarkers</h2>

        <p>When reviewing client labs (with permission and within your scope), focus on these four critical areas that shift during the menopause transition:</p>

        <div class="principle-card">
            <p class="principle-title">1. The Lipid Pivot (LDL & ApoB)</p>
            <p class="principle-text">LDL-C often rises by 10-15% during the transition. However, <span class="highlight">ApoB</span> is a better marker because it counts the actual number of particles. If ApoB is >90 mg/dL, the client is in a high-risk category regardless of their total cholesterol.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">2. Inflammatory Burden (hs-CRP)</p>
            <p class="principle-text">A value >2.0 mg/L indicates systemic inflammation. In menopause, this is often driven by visceral fat accumulation (the "menopause middle") and declining estrogen.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">3. Glycemic Stability (HbA1c & Fasting Insulin)</p>
            <p class="principle-text">Insulin resistance accelerates vascular damage. Aim for a fasting insulin < 7 ¬µIU/mL and HbA1c < 5.4% for optimal vascular protection.</p>
        </div>

        <h2 id="section5">The VITAL Assessment Protocol</h2>

        <p>To implement the 'V' in your coaching practice, use the following 3-step assessment protocol during your initial client intake:</p>

        <ul class="content-list">
            <li><strong>Step 1: Reproductive History Audit.</strong> Ask about age of menarche, pregnancy complications, history of PCOS/Endometriosis, and age of menopause onset.</li>
            <li><strong>Step 2: Symptom Correlation.</strong> Use a validated symptom scale (like the MRS) to grade VMS severity. High scores = higher vascular vigilance.</li>
            <li><strong>Step 3: Lifestyle Metric Review.</strong> Assess current sleep quality (circadian rhythm hygiene), stress levels (cortisol impact on BP), and sedentary time.</li>
        </ul>

        <h2 id="section6">Case Studies & Clinical Application</h2>

        <!-- Case Study 1 -->
        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë©‚Äçüíº</div>
                <div>
                    <p class="box-label">Case Study: The "Low Risk" Misnomer</p>
                    <p class="subtitle">Identifying Hidden Risk in Perimenopause</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, Age 51</h4>
                        <p>Perimenopausal | BMI 24 | Non-smoker</p>
                    </div>
                </div>
                <p><strong>Presenting Symptoms:</strong> Elena felt "healthy" but noticed her blood pressure creeping up to 135/85. Her doctor said her 10-year ASCVD risk was only 2.1% (low risk) and advised "monitoring."</p>
                <p><strong>VITAL Assessment:</strong>
                    <ul>
                        <li>History of Preeclampsia in both pregnancies.</li>
                        <li>Severe night sweats (waking 3x per night).</li>
                        <li>Lipids: LDL 130 mg/dL, but ApoB was 112 mg/dL (High).</li>
                    </ul>
                </p>
                <p><strong>Intervention:</strong> Elena was referred for a Coronary Artery Calcium (CAC) scan, which revealed a score of 85 (placing her in the 90th percentile for her age). Her "low risk" was actually high risk.</p>
                <p><strong>Outcome:</strong> Elena started low-dose HRT for VMS and intensive lifestyle modification (Zone 2 training). Six months later, her BP stabilized at 118/76 and ApoB dropped to 88 mg/dL.</p>
            </div>
        </div>

        <!-- Check Understanding -->
        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of cardiovascular assessment in menopause.</p>

            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is a standard LDL-C measurement sometimes misleading during the menopausal transition?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">LDL-C measures the volume of cholesterol, but menopause often causes a shift toward smaller, denser LDL particles. Measuring ApoB provides a more accurate count of the actual number of atherogenic particles, which is a better predictor of risk.</p>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">A client reports severe hot flashes 10 times per day. According to recent research, what does this indicate about her vascular health?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">Severe and frequent vasomotor symptoms (VMS) are clinical markers for increased subclinical atherosclerosis and impaired endothelial function. This client should be screened more rigorously for other CV risk factors.</p>
            </div>
        </div>

        <!-- Takeaways -->
        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Estrogen is a primary regulator of nitric oxide; its decline leads to immediate increases in arterial stiffness.</li>
                <li>Menopause-specific risk enhancers (early menopause, preeclampsia history, severe VMS) must be included in every assessment.</li>
                <li>ApoB and hs-CRP are superior biomarkers to traditional total cholesterol for assessing menopausal vascular risk.</li>
                <li>Coaches should use the ASCVD Risk Estimator but interpret "low" scores with caution in younger menopausal women.</li>
                <li>Identifying vascular risk early allows for the implementation of the 'V' pillar strategies (movement and nutrition) to prevent clinical events.</li>
            </ul>
        </div>

        <!-- References -->
        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>El Khoudary et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: Implications for Management." <i>Circulation.</i></li>
                <li>Nappi et al. (2022). "The Menopause Transition and Cardiovascular Disease: A Systematic Review." <i>The Lancet Diabetes & Endocrinology.</i></li>
                <li>Samargandy et al. (2021). "Vasomotor Symptoms and Progression of Subclinical Cardiovascular Disease." <i>JAMA Network Open.</i></li>
                <li>Grundy et al. (2019). "AHA/ACC Guideline on the Management of Blood Cholesterol." <i>Journal of the American College of Cardiology.</i></li>
                <li>Maki et al. (2021). "The North American Menopause Society Statement on Vascular Health." <i>Menopause Journal.</i></li>
                <li>Parish et al. (2023). "Apolipoprotein B vs LDL Cholesterol in Women: The Women's Health Study." <i>Clinical Chemistry.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy - Menopause Support Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>